Three market insights:
1. Autologous matrix-induced chondrogenesis is a biological treatment to repair articular cartilage damage. It is designed to slow down cartilage degeneration to avoid or delay knee replacement surgery.
2. In 2016, the global market value was estimated to be $96.11 million, and is expected to increase to $186.4 million by the end of 2024.
3. Factors driving market growth include rising demand for minimally invasive procedures, increasing prevalence of bone and joint disorders and sports injuries as well as greater access.
More articles on biologics:
Dr. Roger Hartl: The biggest opportunity in spinal biologics
Medtronic launches demineralized bone matrix for spine, orthopedics in Japan – 5 key notes
Cardinals’ Carlos Martinez receives PRP injection at Andrews Institute for Orthopaedics and Sports Medicine — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
